ProAxsis announces it has entered into an exclusive licensing agreement with AstraZeneca and will complete the validation and global commercialization of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA test. In AstraZeneca will provide access to intellectual property and technical know-how, and in return will receive an undisclosed royalty fee on future Global net sales of the assay.

Recent Posts

Have Any Questions?

Contact Us


Share This :